Related Experiment Video

Updated: Aug 19, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients

Douglas T Dieterich1

  • 1Gastroenterology and Hepatology, Cabrini Medical Center, New York University School of Medicine, New York, New York 10003, USA. dtdieterich@cs.com

The Journal of Infectious Diseases
|May 10, 2002
PubMed

Insights

Combination therapy with interferon (IFN)-alpha 2b/ribavirin shows promise for treating hepatitis C virus (HCV) in patients co-infected with human immunodeficiency virus (HIV). This treatment approach offers long-term remission for HCV without negatively impacting HIV viral load.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection is prevalent due to shared transmission routes.
  • HIV co-infection exacerbates HCV progression, increasing viral load, liver mortality, and transmission risk.

Purpose of the Study:

  • To evaluate the efficacy and safety of combination interferon (IFN)-alpha 2b/ribavirin therapy in HCV/HIV co-infected individuals.
  • To assess the impact of this combination therapy on HIV RNA concentrations.

Main Methods:

  • Review of preliminary evidence on combination IFN-alpha 2b/ribavirin therapy for HCV/HIV co-infection.
  • Analysis of treatment response rates and adverse effects.

Main Results:

  • Combination therapy achieved comparable response rates to monotherapy in HCV/HIV co-infected patients.
  • No significant adverse effect on HIV RNA concentrations was observed.
  • Adverse effects, though more frequent, were generally manageable, with ribavirin-induced hemolytic anemia being a notable concern manageable with epoetin alfa.

Conclusions:

  • Combination IFN-alpha 2b/ribavirin therapy is a viable option for achieving long-term HCV remission in co-infected individuals.
  • Careful monitoring and management of potential adverse effects, such as anemia, are crucial.

More Related Videos

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis10:12

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Published on: September 11, 2019

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...